Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Want to cut your energy bills? Here’s how five experts are doing it 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017, to discuss its fourth quarter and full-year 2016 financial results and other business highlights.
To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 79789689. The webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.epizyme.com.
March Investor Conferences
In addition, the company will be participating in the following March conferences:
- Cowen and Company 37th Annual Health Care Conference (fireside chat format) on Monday, March 6, 2017 at 4:40 p.m. ET in New York City; and,
- Oppenheimer 27th Annual Healthcare Conference (fireside chat format) on Tuesday, March 21, 2017 at 9:10 a.m. ET in New York City.
Replays of the webcasts of the presentations can be accessed at the investor section of the Company’s website at http://www.epizyme.com.
About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting cancer treatment through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies as a monotherapy and combination therapy and in relapsed and front-line disease. Using the Company’s proprietary platform, Epizyme has pioneered the identification and development of small molecule inhibitors of chromatin modifying proteins (CMPs), such as tazemetostat. CMPs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of CMPs, which can allow cancer cells to grow and proliferate. By focusing on the genetic drivers of cancers, Epizyme's science seeks to match targeted medicines with the specific patients that need it. For more information, visit www.epizyme.com and connect with us on Twitter at @EpizymeRx.
Contacts: Investors Monique Allaire, THRUST IR [email protected] (617) 895-9511 Media Paul Kidwell [email protected] (617) 680-1088
